logo
Share SHARE
FONT-SIZE Plus   Neg

Baxter, Halozyme Issue Update On HyQ Biologics License Application

Baxter International Inc. (BAX) and Halozyme Therapeutics, Inc. (HALO) announced that the U.S. Food and Drug Administration, or FDA, is requesting additional information to complete its review of the HyQ Biologics License Application, or BLA.

Both the companies will work closely together to develop studies to provide additional data to address concerns raised by the FDA related to the long-term chronic use of HyQ. At present, the companies expect to participate in a meeting of the FDA's Blood Products Advisory Committee concerning the agency's request for additional data. The companies expect these requests to require additional time to complete and to delay their anticipated regulatory review and approval timeline.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Nike Inc. (NKE), the world's largest athletic shoes and apparel maker, Tuesday said its first-quarter profit rose 6 percent from a year ago, driven largely by higher revenues. Shares of the company slipped over 6 percent in the after-hours trading, hurt by weak futures orders. Beaverton, Oregon-based... Germany, a clean-power trendsetter country, is planning to introduce hydrogen powered trains. The environment friendly "Coradia iLint" long distance passenger hydrails are expected to be operational by the end of 2017. Rogers Communications Inc. and Shaw Communications Inc. are shutting down Shomi, the subscription video-on-demand service run by the two Canadian companies. Shomi said it will shut down operations on November 30, 2016, just two years since its launch. Shomi was viewed as a Canadian competitor to Netflix.
comments powered by Disqus
Follow RTT